MedTrace Logo

Registry for Hemoperfusion of Covid-19 ICU Patients

NCT05470907 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1050

Last updated 2025-02-13

No results posted yet for this study

Summary

The ongoing COVID-19 pandemic caused high hospitalization and mortality rates especially in critically ill patients. Unfortunately, there is no present study with a large number of patients that would offer us clear answers on the treatment of ICU COVID-19 patients with adsorption filters, extracorporeal methods and the hemoperfusion method. The purpose of this registry study is to investigate the effectiveness and safety of the extracorporeal blood purification and hemoperfusion/hemadsorption filters in treating of critically ill COVID-19 patients.

Conditions

  • COVID-19 Acute Respiratory Distress Syndrome
  • Viral Disease
  • Critical Illness
  • Multi Organ Failure
  • Systemic Inflammatory Response Syndrome
  • AKI - Acute Kidney Injury

Interventions

DEVICE

Hemoperfusion

Commercial membranes for extracorporeal blood purification (hemoperfusion)

Sponsors & Collaborators

  • Clinical Hospital Centre Zagreb

    collaborator OTHER

  • Croatian Society for Organ Support

    lead OTHER

Principal Investigators

  • Vedran Premuzic, M.D., Ph.D. · Clinical Hospital Centre Zagreb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2025-02-01
Completion
2025-02-05
FDA Device
Yes

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05470907 on ClinicalTrials.gov